144 LiuW.YamashitaT.TianF.MorimotoN.IkedaY.DeguchiK.et al (2013)
[There is] difficulty in achieving weight loss in patients with obesity and asthma, which is often made worse by the need for oral steroids to treat flare ups of asthma, Professor Alan Kaplan, chairperson of the Family Physician Airways Group of Canada and the Observational and Pragmatic Research Institute, told Technology Networks
In fact, studies have shown that weight regain is possible once treatment stops if lifestyle habits are not maintained
Entry point for public reimbursement Using the reduced off-patent price as a strong argument for increased access, Canada could become the first market with wide-scale reimbursement of existing primary care medicines, including GLP-1s for diabetes, to designate off-patent semaglutide as the first-line anti-obesity medication (AOM)
Your price stays at $149/mo regardless of dose progression